322 results on '"Gomperts E"'
Search Results
2. ADVATE Inhibitor Risk Profile: 18 Months post-Licensure
3. Current Clinical Investigations Involving FEIBA
4. Efficacy and safety of OBI-1, an antihaemophilic factor VIII (recombinant), porcine sequence, in subjects with acquired haemophilia A
5. Diminished frequency of hepatitis C virus specific interferon (alpha) secreting CD4+ T cells in human immunodeficiency virus/hepatitis C virus coinfected patients
6. F8 haplotype and inhibitor risk: results from the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort
7. Pharmacokinetic properties of IB1001, an investigational recombinant factor IX, in patients with haemophilia B: repeat pharmacokinetic evaluation and sialylation analysis
8. Efficacy and safety of B-domain deleted recombinant porcine factor VIII (OBI-1) in the treatment of acquired hemophilia A: interim results: FP-MO-01.1-1
9. von Willebrand factor: what is its role in the immune response in haemophilia?
10. Suicide among males with hemophilia in the US, 1998–2007: 30P29
11. High frequencies of exposure to the novel human parvovirus, PARV4 in hemophiliacs and injecting drug users detected by a serological assay for PARV4 antibodies: 16P10
12. IB1001, a new recombinant factor IX preparation: initial safety and characterization: OC-MO-086
13. Potency and mass of factor VIII in FVIII products
14. Von Willebrand's disease in the Bantu
15. Haemophilia in the Bantu: Report of 67 cases
16. Long-term major joint outcomes in young adults with haemophilia: interim data from the HGDS
17. A systematic approach to controlling problem bleeds in patients with severe congenital haemophilia A and high-titre inhibitors
18. The parachute must be properly folded …
19. The history of FEIBA: a lifetime of success in the treatment of haemophilia complicated by an inhibitor
20. FEIBA: looking toward the future
21. Considerations in the management of patients with haemophilia and inhibitors
22. FEIBA safety and tolerability profile
23. The need for previously untreated patient population studies in understanding the development of factor VIII inhibitors
24. Diminished frequency of hepatitis C virus specific interferon γ secreting CD4+ T cells in human immunodeficiency virus/hepatitis C virus coinfected patients
25. Long-term major joint outcomes in adults with severe hemophilia: 18 FP 534
26. Approaching the management of bleeding episodes in patients with hemophilia and high-titer inhibitors: 14 PO 428
27. Haemophilia Inhibitor Genetics Study – evaluation of a model for studies of complex diseases using linkage and association methods
28. Haemophilia-related morbidity and quality-of-life
29. Inhibitor development in patients receiving recombinant factor VIII (Recombinate rAHF/Bioclate®): a prospective pharmacovigilance study
30. Frequency and causes of hospitalization in HIV-negative children and adolescents with haemophilia A or B and its effect on academic achievement
31. A model to assess the risk of viral infection with blood products
32. Safety of factor VIII inhibitor bypass activity (FEIBA®): 10-year compilation of thrombotic adverse events
33. Outbreak Of Marburg Virus Disease In Johannesburg
34. Pharmacokinetics, safety and efficacy of a recombinant factor IX product, trenonacog alfa in previously treated haemophilia B patients
35. Summary and conclusions
36. Recombinate study
37. Populational analysis reveals a link between complex viral escape from CD8+ T-Cell responses and protection in HCV infection
38. Potency and mass of factor VIII in factor VIII products
39. ADVATE Inhibitor Risk Profile: 18 Months post-Licensure
40. Current Clinical Investigations Involving FEIBA
41. Genome-Wide Association Study Implicates PARD3B-Based AIDS Restriction
42. von Willebrand factor: what is its role in the immune response in haemophilia?
43. The Effect of Vitamin E on Haemolysis in Paroxysmal Nocturnal Haemoglobinuria: In vitro and in vivo Studies
44. Hepatitis C virus infection and neurocognitive function
45. PPT6: HEMOPHILIA ECONOMIC MODEL OF OUTCOMES: CASE STUDY
46. POD2 DEVELOPMENT OF ECONOMIC AND OUTCOMES MODEL OF HEMOPHILIA TREATMENT IN LATIN AMERICA AND SOUTH
47. Rapid infusion of intravenous immunoglobulin in patients with neuromuscular diseases
48. Pharmacokinetics of Recombinant Factor VIII (Recombinate) Using One-stage Clotting and Chromogenic Factor VIII Assay
49. Ethics of AIDS Study
50. Long-term surveillance for human anti-murine antibodies of a group of haemophiliacs treated only with immunoaffinity-purified FVIII concentrates
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.